Business Wire

More Than 250 Companies Transform Regulatory with Veeva Vault RIM Applications

16.2.2021 15:03:00 EET | Business Wire | Press release

Share

Veeva Systems (NYSE: VEEV) today announced that more than 250 organizations are using Veeva Vault RIM applications for end-to-end regulatory information management. A growing number of emerging biotechs and enterprise companies, including 12 of the top 20 global pharmaceutical companies, are modernizing submission planning, tracking, and publishing to stay ahead of evolving regulations, including the ISO IDMP standards.

“Streamlining regulatory processes is a strategic priority to support efficient submission planning and execution and get medicines to patients faster,” said Dominique Lagrave, head, global regulatory operations at Amgen. “Veeva Vault RIM will unify regulatory processes and deliver the visibility we need to make faster, more informed decisions.”

Life sciences companies of all sizes are rapidly adopting Vault RIM applications to simplify management for product registrations, submission documents, published dossiers, and health authority interactions. Vault RIM removes the reliance on spreadsheets and manual processes so regulatory teams can get the right information to the right person at the right time.

Organizations are leveraging Vault Registrations to support IDMP standards with new entities to better track, manage, and link registered product data. Users can also get a complete view into IDMP data sets based on a product’s current registered details and capture IDMP elements throughout the regulatory process. Now regulatory teams can simplify IDMP implementation for improved quality and compliance.

“More companies are partnering with Veeva to keep pace with changing regulations and bring products to market faster,” said John Lawrie, vice president, Veeva Vault RIM. “Veeva Vault RIM delivers the scale to author and publish thousands of change requests and the innovation to seamlessly manage regulations like IDMP.”

The Veeva Vault RIM Suite includes Vault Registrations, Vault Submissions, Vault Submissions Publishing, and Vault Submissions Archive for unified RIM capabilities on one cloud platform. Vault RIM is part of Veeva Development Cloud, a unified suite of applications for clinical, regulatory, quality, and safety to help organizations drive business processes across R&D and manufacturing.

Watch on-demand Veeva R&D and Quality Summit sessions at veeva.com/Summit to learn how leading companies partner with Veeva to transform regulatory information management.

Additional Information

For more on Veeva Vault RIM, visit: veeva.com/RIM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT5.5.2026 15:00:00 EEST | Press release

Bracco Imaging,a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to evaluate the company’s new BubbleGen™ technology for cell therapy. Bracco’s team will be showcasing BubbleGen, which is designed to support a range of streamlined cell therapy manufacturing processes, at the International Society for Cell & Gene Therapy (ISCT) 2026 conference held this week in Dublin, Ireland. Through the BubbleGen evaluation kit, academic and industry researchers can explore a new approach to cell separation. The technology uses buoyant microbubbles to isolate specific cells, offering an alternative to traditional magnetic bead-based methods. The initial test case supports CD3+ T cell selection and activation in a format commonly used in commercial CAR T-cell therapies, and the platform is designed to extend beyond standard workflows. Researchers can adapt the system to iso

Fleet Launch Customer NetJets Takes Delivery of First Three Cessna Citation Ascend Midsize Business Jets5.5.2026 15:00:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, achieved a major milestone as the first three Cessna Citation Ascend business jets were delivered to fleet launch customer NetJets. NetJets, which operates the world's largest, most diverse private jet fleet, is the first private fleet operator to take delivery and begin operations with the Cessna Citation Ascend. Setting new standards in performance, comfort and operational efficiency for the midsize business jet market, the Citation Ascend builds on the longstanding relationship between Textron Aviation and NetJets by offering owners a seamless progression of advanced aircraft designed to deliver exceptional reliability, efficiency and luxury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505495566/en/ Fleet launch customer NetJets takes delivery of first three Cessna Citation Ascend midsize business jets. (Photo Credit: Textron Aviation) “The Citation Ascend re

ATLAS Infrastructure Cornerstones United Utilities £800m Equity Placement5.5.2026 14:12:00 EEST | Press release

ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing capital on behalf of its funds and long-term institutional clients. ATLAS has been an investor in UU since 2019 and, following the recent equity placement, ATLAS’s actively managed accounts hold a ~6.6% voting and economic interest in United Utilities plc (“UU”). ATLAS recognises the positive new direction established for the UK water sector and welcomes the opportunity to support UU management’s investment plan which will deliver the critical infrastructure required to support housing and industrial growth across North West England, as well as playing a crucial role in supporting nationally important initiatives related to AI data centres and sustainable energy. ATLAS strongly supports UU’s decision to raise new equity in order to accelerate its investment program through providing significant balance sheet capacity and financial flexibility through to the end of AMP8 in 2030. ATLAS values th

Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent5.5.2026 13:37:00 EEST | Press release

Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to Biopharma, today announces the appointments of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent. With extensive senior leadership experience across top-tier life-sciences investment funds, pharma and Biopharma companies, Elaine Caughey and Sarah Shackelton bring deep expertise in life sciences operations, investment, recruitment, and team building. Their appointments are synergistic and aligned with Jeito’s strategy, combining complementary skills across the full drug value chain to support portfolio company development and advance breakthrough therapies for patients. Building on a series of recent high-profile hires — including Samit Hirawat, M.D. as Strategic Medical Advisor, bringing senior leadership and clinical development experience at Novartis and Bristol Myers Squibb; Karin Van Baelen as Chief Regulatory Advisor, with

Datang Mobile, KPN, NEC and Wilus are Latest Licensors to Join Sisvel POS Patent Pool as Incentive Deadline Nears5.5.2026 11:02:00 EEST | Press release

Datang Mobile, KPN, NEC and Wilus have become the latest licensors in the Sisvel point of sale (POS) patent pool. They join seven other patent owners in making their 2G-5G cellular portfolios available through the programme: BlackBerry, Huawei, JVCKENWOOD, LG Electronics, Nokia, Sisvel and SK Telecom. The period for Sisvel POS licensors to benefit from early participation incentives is set to close on 15 May. Cellular patent owners interested in becoming involved should contact Sisvel as soon as possible. The pool, which is the first in the market to address the POS vertical, was announced at the beginning of April, with Huawei, LG Electronics and Nokia as founding licensors. “We have received a great response from the market so far, and I am pleased to welcome Datang, KPN, NEC and Wilus as the latest licensors,” says POS programme manager Sven Törringer. “We have put together a formidable group of cellular technology innovators, and there are many more companies in the pipeline. I am

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye